FEMSelect developed EnPlace – a minimally invasive, mesh-free approach to prolapse repair that has FDA clearance and CE Mark. Women experience minimal pain & recover in days. Standard of care is complex and invasive surgery in a $10B global market. FEMSelect has begun selling the disposable device in Israel and in the US with its US partner, LiNA Medical USA, and is raising a Round B to expand US commercialization.